$100.11
Insights on Glaukos Corp
Revenue is up for the last 2 quarters, 78.04M → 82.36M (in $), with an average increase of 5.2% per quarter
Netprofit is down for the last 2 quarters, -30.44M → -36.77M (in $), with an average decrease of 20.8% per quarter
In the last 3 years, Boston Scientific Corp. has given 72.5% return, outperforming this stock by 67.2%
2.93%
Downside
Day's Volatility :3.07%
Upside
0.15%
54.67%
Downside
52 Weeks Volatility :56.22%
Upside
3.42%
Period | Glaukos Corp | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | 9.09% | 1.1% | 0.0% |
6 Months | 48.8% | 12.5% | 0.0% |
1 Year | 115.25% | 6.9% | 2.2% |
3 Years | 5.31% | 14.3% | -23.0% |
Market Capitalization | 5.1B |
Book Value | $9.4 |
Earnings Per Share (EPS) | -2.78 |
PEG Ratio | 1.64 |
Wall Street Target Price | 106.55 |
Profit Margin | -42.79% |
Operating Margin TTM | -44.46% |
Return On Assets TTM | -7.96% |
Return On Equity TTM | -27.16% |
Revenue TTM | 314.7M |
Revenue Per Share TTM | 6.5 |
Quarterly Revenue Growth YOY | 15.6% |
Gross Profit TTM | 213.9M |
EBITDA | -90.0M |
Diluted Eps TTM | -2.78 |
Quarterly Earnings Growth YOY | 18.96 |
EPS Estimate Current Year | -2.09 |
EPS Estimate Next Year | -1.29 |
EPS Estimate Current Quarter | -0.55 |
EPS Estimate Next Quarter | -0.55 |
What analysts predicted
Upside of 6.43%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 181.3M | ↑ 13.83% |
Net Income | -13.0M | ↑ 13977.17% |
Net Profit Margin | -7.14% | ↓ 7.08% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 237.0M | ↑ 30.73% |
Net Income | 15.4M | ↓ 219.1% |
Net Profit Margin | 6.51% | ↑ 13.65% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 225.0M | ↓ 5.07% |
Net Income | -120.3M | ↓ 880.26% |
Net Profit Margin | -53.5% | ↓ 60.01% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 294.0M | ↑ 30.7% |
Net Income | -49.6M | ↓ 58.79% |
Net Profit Margin | -16.87% | ↑ 36.63% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 282.9M | ↓ 3.79% |
Net Income | -99.2M | ↑ 100.02% |
Net Profit Margin | -35.07% | ↓ 18.2% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 314.7M | ↑ 11.26% |
Net Income | -134.7M | ↑ 35.75% |
Net Profit Margin | -42.79% | ↓ 7.72% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Revenue | 71.3M | ↓ 1.95% |
Net Income | -27.6M | ↓ 39.44% |
Net Profit Margin | -38.69% | ↑ 23.96% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 71.2M | ↓ 0.06% |
Net Income | -31.5M | ↑ 14.08% |
Net Profit Margin | -44.17% | ↓ 5.48% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 73.9M | ↑ 3.75% |
Net Income | -34.6M | ↑ 10.06% |
Net Profit Margin | -46.86% | ↓ 2.69% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 80.4M | ↑ 8.8% |
Net Income | -32.8M | ↓ 5.24% |
Net Profit Margin | -40.81% | ↑ 6.05% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 78.0M | ↓ 2.92% |
Net Income | -30.4M | ↓ 7.22% |
Net Profit Margin | -39.01% | ↑ 1.8% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 82.4M | ↑ 5.53% |
Net Income | -36.8M | ↑ 20.81% |
Net Profit Margin | -44.65% | ↓ 5.64% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 207.0M | ↑ 24.8% |
Total Liabilities | 33.1M | ↑ 19.82% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 818.4M | ↑ 295.42% |
Total Liabilities | 145.1M | ↑ 338.32% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 1.0B | ↑ 22.86% |
Total Liabilities | 338.1M | ↑ 132.93% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 1.0B | ↑ 4.4% |
Total Liabilities | 462.5M | ↑ 36.83% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 1.0B | ↓ 4.51% |
Total Liabilities | 472.4M | ↑ 2.13% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 940.4M | ↓ 6.18% |
Total Liabilities | 478.6M | ↑ 1.33% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 1.0B | ↓ 2.21% |
Total Liabilities | 459.9M | ↓ 1.9% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 1.0B | ↓ 0.6% |
Total Liabilities | 472.4M | ↑ 2.71% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 972.6M | ↓ 2.97% |
Total Liabilities | 464.1M | ↓ 1.76% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 956.7M | ↓ 1.63% |
Total Liabilities | 467.9M | ↑ 0.83% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 948.6M | ↓ 0.85% |
Total Liabilities | 471.0M | ↑ 0.65% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 940.4M | ↓ 0.87% |
Total Liabilities | 478.6M | ↑ 1.63% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 18.9M | ↓ 26.05% |
Investing Cash Flow | -26.4M | ↑ 125.12% |
Financing Cash Flow | 21.6M | ↑ 362.31% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -369.0K | ↓ 101.96% |
Investing Cash Flow | 43.4M | ↓ 264.49% |
Financing Cash Flow | -9.6M | ↓ 144.7% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -23.0M | ↑ 6129.81% |
Investing Cash Flow | -205.1M | ↓ 572.21% |
Financing Cash Flow | 262.5M | ↓ 2822.05% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 24.7M | ↓ 207.48% |
Investing Cash Flow | -58.2M | ↓ 71.6% |
Financing Cash Flow | 39.3M | ↓ 85.05% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -33.1M | ↓ 233.9% |
Investing Cash Flow | 44.8M | ↓ 176.9% |
Financing Cash Flow | 6.3M | ↓ 84.08% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -26.5M | ↑ 117.23% |
Investing Cash Flow | 24.4M | ↑ 153.28% |
Financing Cash Flow | 4.2M | ↑ 3867.92% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -4.1M | ↓ 84.4% |
Investing Cash Flow | 16.7M | ↓ 31.72% |
Financing Cash Flow | 529.0K | ↓ 87.42% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -30.8M | ↑ 643.81% |
Investing Cash Flow | -13.8M | ↓ 183.05% |
Financing Cash Flow | 1.2M | ↑ 117.77% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -8.2M | ↓ 73.47% |
Investing Cash Flow | 26.0M | ↓ 287.62% |
Financing Cash Flow | -880.0K | ↓ 176.39% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -8.2M | ↑ 0.09% |
Investing Cash Flow | 14.9M | ↓ 42.6% |
Financing Cash Flow | 7.5M | ↓ 948.52% |
Sell
Neutral
Buy
Glaukos Corp is currently in a neutral trading position according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Glaukos Corp | 13.76% | 48.8% | 115.25% | 5.31% | 41.4% |
Stryker Corporation | -3.86% | 30.27% | 12.73% | 26.98% | 78.91% |
Dexcom, Inc. | -1.59% | 63.45% | 11.22% | 31.69% | 366.88% |
Boston Scientific Corp. | 7.32% | 46.46% | 42.68% | 72.49% | 95.05% |
Abbott Laboratories | -2.84% | 13.74% | -1.71% | -12.8% | 36.06% |
Medtronic Plc | -3.97% | 14.22% | -10.66% | -38.23% | -7.98% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Glaukos Corp | NA | NA | 1.64 | -2.09 | -0.27 | -0.08 | NA | 9.4 |
Stryker Corporation | 40.64 | 40.64 | 2.92 | 11.85 | 0.18 | 0.07 | 0.01 | 48.92 |
Dexcom, Inc. | 102.89 | 102.89 | 2.53 | 1.76 | 0.26 | 0.06 | NA | 5.37 |
Boston Scientific Corp. | 64.48 | 64.48 | 1.8 | 2.25 | 0.09 | 0.04 | NA | 13.16 |
Abbott Laboratories | 33.52 | 33.52 | 5.99 | 4.31 | 0.15 | 0.06 | 0.02 | 22.26 |
Medtronic Plc | 25.81 | 25.81 | 1.52 | 5.2 | 0.08 | 0.04 | 0.03 | 38.95 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Glaukos Corp | Buy | $5.1B | 41.4% | NA | -42.79% |
Stryker Corporation | Buy | $127.4B | 78.91% | 40.64 | 15.44% |
Dexcom, Inc. | Buy | $54.6B | 366.88% | 102.89 | 14.95% |
Boston Scientific Corp. | Buy | $101.4B | 95.05% | 64.48 | 11.18% |
Abbott Laboratories | Buy | $186.7B | 36.06% | 33.52 | 13.96% |
Medtronic Plc | Buy | $107.9B | -7.98% | 25.81 | 13.0% |
BlackRock Inc
FMR Inc
Vanguard Group Inc
Brown Capital Management, LLC
State Street Corporation
Fred Alger Management, LLC
Glaukos Corp’s price-to-earnings ratio stands at None
Read Moreglaukos corporation is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures to transform the treatment of glaucoma, one of the world’s leading causes of blindness. glaukos has pioneered micro-invasive glaucoma surgery, or migs, to revolutionize the traditional glaucoma treatment and management paradigm. the company launched the istent trabecular micro-bypass stent, its first migs device, in the united states in 2012. glaukos is leveraging its platform technology to build a comprehensive and proprietary portfolio of injectable micro-scale therapies designed to address the complete range of glaucoma disease states and progression. glaukos believes the istent is the smallest medical device ever approved by the food and drug administration, or fda, measuring 1.0 mm long and 0.33 mm wide. in june 2015, the company completed an initial public offering and its shares are now traded on the new york stock exchange unde
Organization | Glaukos Corp |
Employees | 907 |
CEO | Mr. Thomas William Burns |
Industry | Health Technology |
Cerevel Therapeutics Holdings Inc
$100.11
-0.81%
Site Centers Corp.
$100.11
-0.81%
Agree Realty Corp
$100.11
-0.81%
Dlocal Limited
$100.11
-0.81%
Korn/ferry International
$100.11
-0.81%
Fulton Financial Corp
$100.11
-0.81%
Vail Resorts Inc.
$100.11
-0.81%
Ishares Msci Kld 400 Social Etf
$100.11
-0.81%
One Gas Inc
$100.11
-0.81%